inobrodib

News

CellCentric's chief executive, Will West

CellCentric pockets $220m for blood cancer programme

CellCentric has raised $220 million in a Series D financing that will help fund pivotal trials of p300/CBP inhibitor inobrodib in multiple myeloma.

Digital

pharmaphorum podcast Episode 261 - Kris Kaneta, Norstella

Trustworthy and novel AI in clinical trial planning, with Kr...

Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks